"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1995 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 5 | 6 |
| 2003 | 0 | 11 | 11 |
| 2004 | 0 | 8 | 8 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 5 | 6 |
| 2008 | 2 | 6 | 8 |
| 2009 | 1 | 8 | 9 |
| 2010 | 0 | 9 | 9 |
| 2011 | 3 | 8 | 11 |
| 2012 | 4 | 8 | 12 |
| 2013 | 4 | 5 | 9 |
| 2014 | 6 | 3 | 9 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 4 | 5 | 9 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 6 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247.
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
-
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622.
-
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914.
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282.
-
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021 08 20; 373(6557):931-936.
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021 06; 150:83-94.
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088.
-
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 04 20; 39(12):1371-1382.